Yes, good morning, sir. So, I just had a clarification about the Revlimid. We are expecting one- third quantity this year. Can you give a ballpark market total size out of which we will get the one-third share?
Yes, out of which we will get the one third of what?
Congratulations for the good set of numbers. I had 2 questions. First, can you give a highlight of the new investment into the eGenesis, the biotech company? What's your plan here?
Understood, sir. And the second question, do we plan any major M&A coming here in the next year. We have a lot of cash on our books.
Congratulations for the great set of numbers and meeting the guidance which you provided. I just wanted to understand with so much cash in hand, do we have any significant CAPEX plan this year?
And sir, I just wanted to have a brief about how is the demand shaping up for the export customers, like all the geopolitical crisis, Red Sea crisis, has this affected Natco or not?